» Articles » PMID: 19720758

The Major Neutralizing Antibody Responses to Recombinant Anthrax Lethal and Edema Factors Are Directed to Non-cross-reactive Epitopes

Overview
Journal Infect Immun
Date 2009 Sep 2
PMID 19720758
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Anthrax lethal and edema toxins (LeTx and EdTx, respectively) form by binding of lethal factor (LF) or edema factor (EF) to the pore-forming moiety protective antigen (PA). Immunity to LF and EF protects animals from anthrax spore challenge and neutralizes anthrax toxins. The goal of the present study is to identify linear B-cell epitopes of EF and to determine the relative contributions of cross-reactive antibodies of EF and LF to LeTx and EdTx neutralization. A/J mice were immunized with recombinant LF (rLF) or rEF. Pools of LF or EF immune sera were tested for reactivity to rLF or rEF by enzyme-linked immunosorbent assays, in vitro neutralization of LeTx and EdTx, and binding to solid-phase LF and EF decapeptides. Cross-reactive antibodies were isolated by column absorption of EF-binding antibodies from LF immune sera and by column absorption of LF-binding antibodies from EF immune sera. The resulting fractions were subjected to the same assays. Major cross-reactive epitopes were identified as EF amino acids (aa) 257 to 268 and LF aa 265 to 274. Whole LF and EF immune sera neutralized LeTx and EdTx, respectively. However, LF sera did not neutralize EdTx, nor did EF sera neutralize LeTx. Purified cross-reactive immunoglobulin G also failed to cross-neutralize. Cross-reactive B-cell epitopes in the PA-binding domains of whole rLF and rEF occur and have been identified; however, the major anthrax toxin-neutralizing humoral responses to these antigens are constituted by non-cross-reactive epitopes. This work increases understanding of the immunogenicity of EF and LF and offers perspective for the development of new strategies for vaccination against anthrax.

Citing Articles

Development of a novel multiepitope chimeric vaccine against anthrax.

Aggarwal S, Somani V, Gupta S, Garg R, Bhatnagar R Med Microbiol Immunol. 2019; 208(2):185-195.

PMID: 30671633 DOI: 10.1007/s00430-019-00577-x.


Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.

Dumas E, Gross T, Larabee J, Pate L, Cuthbertson H, Charlton S Clin Vaccine Immunol. 2017; 24(11).

PMID: 28877928 PMC: 5674197. DOI: 10.1128/CVI.00165-17.


CD4+ T Cells Targeting Dominant and Cryptic Epitopes from Bacillus anthracis Lethal Factor.

Ascough S, Ingram R, Chu K, Musson J, Moore S, Gallagher T Front Microbiol. 2016; 6:1506.

PMID: 26779161 PMC: 4700811. DOI: 10.3389/fmicb.2015.01506.


An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Ohanjanian L, Remy K, Li Y, Cui X, Eichacker P Expert Opin Investig Drugs. 2015; 24(7):851-65.

PMID: 25920540 PMC: 5579489. DOI: 10.1517/13543784.2015.1041587.


Protective antigen-specific memory B cells persist years after anthrax vaccination and correlate with humoral immunity.

Garman L, Smith K, Farris A, Nelson M, Engler R, James J Toxins (Basel). 2014; 6(8):2424-31.

PMID: 25123559 PMC: 4147590. DOI: 10.3390/toxins6082424.


References
1.
Salles I, Voth D, Ward S, Averette K, Tweten R, Bradley K . Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1. Cell Microbiol. 2006; 8(8):1272-81. DOI: 10.1111/j.1462-5822.2006.00708.x. View

2.
Zhou B, Carney C, Janda K . Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg Med Chem. 2007; 16(4):1903-13. PMC: 2268906. DOI: 10.1016/j.bmc.2007.11.001. View

3.
Farris A, Brown L, Reynolds P, Harley J, James J, Scofield R . Induction of autoimmunity by multivalent immunodominant and subdominant T cell determinants of La (SS-B). J Immunol. 1999; 162(5):3079-87. View

4.
Juris S, Melnyk R, Bolcome 3rd R, Chan J, Collier R . Cross-linked forms of the isolated N-terminal domain of the lethal factor are potent inhibitors of anthrax toxin. Infect Immun. 2007; 75(10):5052-8. PMC: 2044540. DOI: 10.1128/IAI.00490-07. View

5.
Flick-Smith H, Waters E, Walker N, Miller J, Stagg A, Green M . Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb Pathog. 2005; 38(1):33-40. DOI: 10.1016/j.micpath.2004.10.007. View